DOCK2 and DOCK5 Act Additively in Neutrophils To Regulate Chemotaxis, Superoxide Production, and Extracellular Trap Formation

Mayuki Watanabe, Masao Terasawa, Kei Miyano, Toyoshi Yanagihara, Takehito Uruno, Fumiyuki Sanematsu, Akihiko Nishikimi, Jean-François Côté, Hideki Sumimoto and Yoshinori Fukui

*J Immunol* published online 22 October 2014
http://www.jimmunol.org/content/early/2014/10/19/jimmunol.1400885

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
DOCK2 and DOCK5 Act Additively in Neutrophils To Regulate Chemotaxis, Superoxide Production, and Extracellular Trap Formation

Mayuki Watanabe,* Masao Terasawa,* Kei Miyano,† Toyoshi Yanagihara,* Takehito Urano,* Fumiyuki Sanematsu,* Akihiko Nishikimi,‡ Jean-François Côté,§ Hideki Sumimoto,* and Yoshihori Fukui*‡*

Neutrophils are highly motile leukocytes that play important roles in the innate immune response to invading pathogens. Neutrophils rapidly migrate to the site of infections and kill pathogens by producing reactive oxygen species (ROS). Neutrophil chemotaxis and ROS production require activation of Rac small GTPase. DOCK2, an atypical guanine nucleotide exchange factor (GEF), is one of the major regulators of Rac in neutrophils. However, because DOCK2 deficiency does not completely abolish fMLF-induced Rac activation, other Rac GEFs may also participate in this process. In this study, we show that DOCK5 acts with DOCK2 in neutrophils to regulate multiple cellular functions. We found that fMLF- and PMA-induced Rac activation were almost completely lost in mouse neutrophils lacking both DOCK2 and DOCK5. Although β2 integrin-mediated adhesion occurred normally even in the absence of DOCK2 and DOCK5, mouse neutrophils lacking DOCK2 and DOCK5 exhibited a severe defect in chemotaxis and ROS production. Similar results were obtained when human neutrophils were treated with CPYPP, a small-molecule inhibitor of these DOCK GEFs. Additionally, we found that DOCK2 and DOCK5 regulate formation of neutrophil extracellular traps (NETs). Because NETs are involved in vascular inflammation and autoimmune responses, DOCK2 and DOCK5 would be a therapeutic target for controlling NET-mediated inflammatory disorders.

The Journal of Immunology, 2014, 193: 000–000.
in neutrophils. However, because DOCK2 deficiency does not completely abolish Rac activation (14), it is conceivable that other Rac GEFs also participate in this process.

Unlike Dbl-GEFs, the DOCK proteins contain a unique DOCK homology region (DHR)-2 (also known as Dockor or CZH2) domain mediating nucleotide exchange on Rac or Cdc42 (10, 16, 17). These GEFs also contain a DHR-1 signature domain that serves to localize the proteins at the membrane, via binding to phospholipids, for GTPase activation (10, 18). This family consists of 11 members subdivided into four subfamilies (DOCK-A, -B, -C, and -D) based on their sequence homology and substrate specificity. For example, DOCK1 and DOCK5, as well as DOCK2, belong to the DOCK-A subfamily and act as Rac-specific GEFs (10, 19). DOCK1 and DOCK5 are widely expressed in various tissues and regulate multiple cellular functions, including myoblast fusion, bone resorption, and migration (20–22); however, their roles in the immune system and immune responses are poorly understood. We found that neutrophils also express DOCK5, but not DOCK1. In this study, we demonstrate that DOCK5 acts with DOCK2 in neutrophils to regulate chemotaxis, ROS production, and formation of neutrophil extracellular traps (NETs) (23).

Materials and Methods

Mice

DOCK5- and DOCK2-deficient (DOCK5⁻/⁻ and DOCK2⁻/⁻) mice have been previously described (20, 21, 24). These mice were backcrossed onto a C57BL/6 background for more than eight generations prior to analyses, and age- and sex-matched C57BL/6 mice were used as wild-type (WT) controls. The animals were maintained in specific pathogen-free conditions and age- and sex-matched C57BL/6 mice were used as wild-type (WT) controls. The animals were maintained in specific pathogen-free conditions in the animal facility of Kyushu University. All experiments were done in accordance with the guidelines of the Committee of Ethics of Animal Experiments, Kyushu University.

Neutrophil isolation

Mouse bone marrow (BM) neutrophils were isolated from femurs and tibias of mice and layered onto a discontinuous Percoll (GE Healthcare) gradient. After centrifugation, cells at the 62/81% interface were recovered and washed twice with HBSS (Invitrogen). More than 90% of the recovered cells were Gr-1⁻CD11b⁺ mature neutrophils. Human neutrophils were isolated from peripheral blood of healthy donors. Blood samples were mixed with an equal volume of 2% dextran solution by repeated inversion and tubes were set upfright for 30 min at room temperature. The straw-colored, leukocyte-rich, erythrocyte-poor upper layer was put onto Histopaque-1077 (Sigma-Aldrich). After centrifugation, pellets were washed with HBSS followed by hemolysis.

Rac activation assays

Mouse BM neutrophils suspended in HBSS were stimulated with fMLF (10 μM) or PMA (100 nM). Aliquots of the cell extracts were kept for total lysate controls, and the remaining extracts were incubated with the GST-fusion Rac-binding domain of PKA at 4°C for 60 min. The bound proteins and the total lysate control (5 μg for Rac1 and 2 μg for Rac2) were analyzed by SDS-PAGE, and bands were probed with anti-Rac1 (23A8, Millipore) and anti-Rac2 (3B10-2D9, Sigma-Aldrich) Abs. In some experiments, human peripheral blood neutrophils were treated with CPYPP (100 μM), a small-molecule inhibitor of DOCK-A subfamily members (25–27), for 60 min before stimulation with fMLF (10 μM).

Immunoblot analysis

Mouse BM neutrophils suspended in HBSS were stimulated with fMLF (10 μM) or PMA (100 nM) for the indicated time. Reactions were terminated by adding an equal volume of Laemmli sample buffer (125 mM Tris-HCl, 4% SDS, 20% glycerol, 0.01% bromophenacyl bromide [pH 6.8]) supplemented with 2 mM EGTA, 100 μM DTT, and complete protease inhibitors (Roche), and samples were boiled for 10 min for analyses by immunoblotting. Activation of ERKs, Akt, p38, and MEK was assessed with phosphorylation-specific Abs against Thr202/Tyr204 of p44 and p42 ERKs, Ser277 of Akt, Thr180/Tyr182 of p38, and Ser217/Ser221 of MEK (all from Cell Signaling Technology). The expression of DOCK-A subfamily members, P-Rex1 and Vav, was examined by immunoblotting using anti-DOCK1 (C4C12, Cell Signaling Technology), anti-DOCK2 (Millipore), anti-DOCK5, anti–P-Rex1 (6F12, Millipore), and anti-Vav (C-14, Santa Cruz Biotechnology) Abs. The polyclonal Ab against DOCK5 was produced by immunizing a rabbit with keyhole limpet hemocyanin–coupled synthetic peptide corresponding to the C-terminal sequence (PKARKS-GILSSEPGSQ, residues 1853–1868) of mouse DOCK5.

Chromatex assay

Mouse BM neutrophils and human peripheral blood neutrophils with or without CPYPP treatment were allowed to migrate under the fMLF gradient (10–100 μM) or CXCL2 (0–1 μg/ml) gradient in an EZ-TAXIScan chamber (Effector Cell Institute). Phase contrast images of chemotaxing cells were acquired at 30-s intervals during 20 min. Images were imported as stacks to ImageJ (National Institutes of Health, Bethesda, MD) and analyzed with the manual tracking and the chemotaxis and migration tools.

Immunofluorescence microscopy

Mouse BM neutrophils migrating in an EZ-TAXIScan chamber along the fMLF gradient were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS. After being suspended in PBS containing 1% BSA, cells were stained with Alexa Fluor 546–conjugated phallolidin and DAPI for 20 min at room temperature and washed twice with the same buffer. Microscopic analysis was performed with a laser scanning confocal microscope (LSM 510 META, Carl Zeiss).

ROS production

Mouse BM neutrophils (5 × 10⁶/ml) suspended in serum-free RPMI 1640 medium were seeded on poly-γ-glutamic acid–coated glass-bottom dishes (MatTek). Cells were stimulated with PMA (20 nM) for 18 h at 37°C, and samples were stained with Sytox Green (for live cells) and Sytox Orange (for NETs; both from Invitrogen). Quantification of NETs was performed as described (28). Briefly, NETs were incubated in the presence of 500 nM nuclease for 15 min. Nuclease activity was stopped with 5 mM EDTA, and insoluble debris was removed by centrifugation. Total DNA was extracted from neutrophils with DNAzol (Invitrogen) supplemented with 1% polyacryl carrier (Molecular Research Center) and dissolved in TE buffer. DNA was quantified with a PicoGreen dsDNA kit (Invitrogen). Percentage of NET DNA was calculated by dividing the amount of NET DNA by the total amount of DNA.

Adhesion assay

Mouse BM neutrophils suspended in HBSS containing 20 mM HEPEs (pH 7.4) and 0.1% BSA were stimulated with fMLF (10 μM) or PMA (162.12 nM). Cells were then allowed to adhere for 30 min at 37°C in 96-well plates coated with ICAM-1 and C3bi. Wells were washed twice with HBSS containing 20 mM HEPEs (pH 7.4) and 0.1% BSA, and adherent neutrophils were quantified using a CytoTox 96 nonradioactive cytotoxicity assay system (Promega).

Statistical analysis

Statistical analysis was performed using analysis of Kruskal–Wallis H test or variance (ANOVA) followed by a two-tailed multiple t test with a Bonferroni correction.

Results

DOCK2 and DOCK5 act additively to regulate chemotactant-induced Rac activation in mouse BM neutrophils

Western blot analysis revealed that mouse neutrophils express DOCK2 and DOCK5, but not DOCK1 (Fig. 1A). This finding led us to examine the extent of functional overlap between these Rac GEFs and DOCK5.
GEFs in neutrophil functions. When the expression of CD11b and Gr-1 on freshly isolated BM neutrophils was compared among WT, DOCK2<sup>2−/2</sup>, DOCK5<sup>2−/2</sup>, and DKO mice lacking both DOCK2 and DOCK5, no difference was found, indicating that deficiency of DOCK2 and/or DOCK5 does not affect neutrophil maturation (Fig. 1B). In WT BM neutrophils stimulated with the bacterial peptide fMLF, activated Rac1 and Rac2 were readily detected at 5 and 15 s (Fig. 1C). This Rac activation was substantially reduced in DOCK2<sup>−/−</sup> neutrophils, whereas DOCK5 deficiency alone showed only modest effect (Fig. 1C, 1D). However, fMLF-induced activation of Rac1 and Rac2 was reduced in DKO neutrophils to 12.3 and 19.9% of the WT levels at 15 s after

FIGURE 1. DOCK2 and DOCK5 act additively in regulation of GPCR-mediated Rac activation. (A) Expression of DOCK-A family proteins in BM neutrophils, splenocytes, and mouse embryonic fibroblasts (MEFs). Cell lysates were subjected to immunoblotting using anti-DOCK1, -DOCK2, and -DOCK5 Abs. Data are representative of two independent experiments. (B) Flow cytometric analysis for the expression of Gr-1 and CD11b on BM neutrophils from WT, DOCK2<sup>−/−</sup>, DOCK5<sup>−/−</sup>, and DKO mice. Numbers indicate the percentages of Gr-1<sup>−/−</sup>CD11b<sup>+</sup> cells in purified BM neutrophils. Data are representative of more than three independent experiments. (C and D) Activation of Rac1 and Rac2 in BM neutrophils from WT, DOCK2<sup>−/−</sup>, DOCK5<sup>−/−</sup>, and DKO mice stimulated with fMLF (10 μM) for the indicated times. Cell lysates were subjected to pull-down assays using GST-fusion Rac-binding domain of PAK1 before immunoblotting with anti-Rac1 and -Rac2 Abs. Results were quantified by densitometry and are expressed as the ratio of the GTP-bound form to total protein after normalization of the 15 s value of WT neutrophils to an arbitrary value of 1. Data are indicated as means ± SEM of three separate experiments. *p < 0.05, **p < 0.01. (E) Expression of DOCK2, DOCK5, P-Rex1, and Vav proteins in BM neutrophils from WT, DOCK2<sup>−/−</sup>, DOCK5<sup>−/−</sup>, and DKO mice. Cell lysates were subjected to immunoblotting using anti-DOCK2, -DOCK5, –P-Rex1, and -Vav Abs. Data are representative of two independent experiments. (F and G) Phosphorylations of ERK, Akt, and p38 in BM neutrophils from WT, DOCK2<sup>−/−</sup>, DOCK5<sup>−/−</sup>, and DKO mice stimulated with fMLF (10 μM) for the indicated times. Cell lysates were subjected to immunoblotting using phosphorylation-specific Abs against ERK, Akt, and p38. Results were quantified by densitometry and are expressed as the ratio of phosphorylated form to total protein after normalization of the WT value (2 min value for ERK and Akt, 5 min value for p38) to an arbitrary value of 1. Data are indicated as means ± SEM of three separate experiments. *p < 0.05, **p < 0.01.
stimulation (Fig. 1C, 1D). Similar defects were observed when these neutrophils were stimulated with chemokine CXCL2 (data not shown). Because the expression level of DOCK2 in DOCK52/2 neutrophils or DOCK5 in DOCK22/2 neutrophils was comparable to that of the WT control (Fig. 1E), it is clear that the exacerbated phenotype observed in DKO neutrophils does not reflect loss of compensatory upregulation of the other member in single-deficient neutrophils. Additionally, we found that deficiency of DOCK2 and DOCK5 does not affect the expression level of Dbl-GEFs such as P-Rex1 and Vav (Fig. 1E). These results indicate that DOCK2 and DOCK5 act additively to regulate Rac activation in response to G protein–coupled receptor (GPCR) stimulation. It has been reported that chemoattractant-induced phosphorylations of ERK and Akt are severely impaired in neutrophils lacking
both Rac1 and Rac2, as compared with those in single-deficient neutrophils (6, 7). To further examine the effect of DOCK2/DOCK5 double deficiency on GPCR signaling, we compared phosphorylation status of these molecules among WT, DOCK2−/−, DOCK5−/−, and DKO neutrophils. Upon stimulation with fMLF, ERK, Akt, and also p38 were phosphorylated in WT neutrophils (Fig. 1F). These phosphorylations were diminished to 46.2, 76.3, and 53.4% of the WT level, respectively, but were still observed in DOCK2−/− neutrophils (Fig. 1F, 1G). However, consistent with the defect in Rac activation, phosphorylations of ERK, Akt, and p38 were almost completely abolished in DKO neutrophils (Fig. 1F, 1G). These results further indicate that DOCK5 and DOCK2 act additively in the GPCR-mediated signal transduction pathway.

DOCK2 and DOCK5 additively regulate GPCR-mediated neutrophil functions in mice

Having found that DOCK2 and DOCK5 regulate GPCR-mediated Rac activation in mouse BM neutrophils, we examined the effect of DOCK2 and/or DOCK5 deficiency on neutrophil chemotaxis. In a chemotaxis assay using an EZ-TAXIScan chamber, WT neutrophils actively migrated toward the fMLF source at the speed of 8.7 μm/min (Fig. 2A). Although the average speed of DOCK2−/− neutrophils was reduced to <61% of the WT level, DOCK5 deficiency alone did not significantly affect motility (Fig. 2A). However, DKO neutrophils clearly showed a more severe defect than did DOCK2−/− neutrophils, and they could hardly migrate toward the fMLF source (Fig. 2A). Similar results were obtained when BM neutrophils chemotaxing along the CXCL2 gradient were analyzed (Fig. 2B). Consistent with this finding, most DKO neutrophils undergoing chemotaxis exhibited abnormal morphology with poorly focused distribution of F-actin (Fig. 2C).

As Rac is a cytosolic component of NADPH oxidase (1, 2), we next compared ROS production among WT, DOCK2−/−, DOCK5−/−, and DKO neutrophils. When WT neutrophils were stimulated with fMLF, they produced ROS in a superoxide dismutase–inhibitable manner (Fig. 2D). Although ROS production by DOCK2−/− neutrophils was decreased to 35.7% of that of WT neutrophils, DOCK5 deficiency alone showed only modest effect (Fig. 2D, 2E). In the absence of both DOCK2 and DOCK5, however, fMLF-induced ROS production was further reduced to 19.4% of the WT level (Fig. 2D, 2E). Collectively, these results indicate that DOCK2 and DOCK5 act additively in mouse neutrophils to regulate the GPCR-mediated chemotactic response and ROS production.

A small-molecule inhibitor of DOCK2/DOCK5 suppresses human neutrophil functions

To examine whether the role of DOCK2 and DOCK5 could be extended to human neutrophils, we used CPYPP, a small-molecule inhibitor that binds to the DHR-2 domain of DOCK-A subfamily members and inhibits their Rac GEF activity (25–27). As expected, treatment of human peripheral blood neutrophils with CPYPP at 100 μM reduced fMLF-induced Rac2 activation to 22.5% of the vehicle (DMSO)-treated samples (Fig. 3A, 3B). Consistent with this finding, CPYPP inhibited chemotactic response in a dose-dependent manner (Fig. 3C, 3D). Additionally, fMLF-induced ROS production was almost completely lost when human peripheral blood neutrophils were treated with CPYPP at 100 μM (Fig. 3E). These results indicate that DOCK2 and DOCK5 regulate GPCR-mediated neutrophil functions in humans through their Rac GEF activity.

DOCK2 and DOCK5 additively regulate PMA-induced Rac activation and ROS production

PMA, an activator of protein kinase C, induces a slow but sustained activation of Rac, independently of PI3K activation (29). To examine how DOCK2 and/or DOCK5 deficiency affects PMA-induced Rac activation, we stimulated mouse BM neutrophils with 100 nM PMA. Although activated Rac1 and Rac2 were readily detected in WT and DOCK5−/− neutrophils at 1 and 2 min after stimulation, such activation was severely impaired in both DOCK2−/− and DKO neutrophils (Fig. 4A, 4B). It is likely that DOCK2 and DOCK5 also act additively in this pathway, because PMA-induced ROS production was further reduced in DKO neutrophils, as compared with that in DOCK2−/− neutrophils (10.4 versus 20.2% of the WT level; Fig. 4C, 4D). Similar results were obtained when ROS production was measured by the cytochrome c assay (Fig. 4E). In contrast, unlike the GPCR-mediated stimulation, PMA-induced activation of ERK and MEK, which were measured with phosphorylation-specific Abs, occurred normally even in the DKO neutrophils (Fig. 4F, 4G).
DOCK2 and DOCK5 additively regulate NET formation

Neutrophils stimulated with microbes or proinflammatory agents release their own DNA, histones, proteases, and other antimicrobial molecules, forming a web-like extracellular network designated as NETs (23). Although NETs play important roles in trapping and killing microorganisms to prevent spread of infection, NET formation has been also implicated in vascular inflammation and autoimmune diseases (30–33). To examine the effect of DOCK2 and/or DOCK5 deficiency on NET formation, we stimulated mouse BM neutrophils with PMA, a potent inducer of NETosis in vitro. WT and DOCK2−/−, DOCK5−/−, and DKO mice stimulated with PMA (100 nM) for the indicated times. Cell lysates were subjected to pull-down assays using GST-fusion Rac-binding domain of PAK1 before immunoblotting with anti-Rac1 and -Rac2 Abs. Results were quantified by densitometry and are expressed as the ratio of GTP-bound Rac to total protein after normalization of the 2 min value of WT neutrophils to an arbitrary value of 1. Data are indicated as means ± SEM of three separate experiments. *p < 0.05, **p < 0.01. (C and D) ROS production was compared among WT, DOCK2−/−, DOCK5−/−, and DKO neutrophils stimulated with PMA (324.24 nM). In (C), the right panel indicates the magnified view of the graph to show the difference between DOCK2−/− and DKO neutrophils. In (D), results are expressed as the ratio after normalization of the WT value to an arbitrary value of 1. Data are indicated as means ± SD of triplicate samples. **p < 0.01. (E) ROS production by WT, DOCK2−/−, DOCK5−/−, and DKO neutrophils stimulated with PMA (324.24 nM) was measured by means of a cytochrome c reduction assay. Data are indicated as means ± SD of triplicate samples. *p < 0.05, **p < 0.01. (F and G) Phosphorylations of ERK and MEK in BM neutrophils from WT, DOCK2−/−, DOCK5−/−, and DKO mice stimulated with PMA (100 nM) for the indicated times. Cell lysates were subjected to immunoblotting using phosphorylation-specific Abs against ERK and MEK. Results were quantified by densitometry and are expressed as the ratio of phosphorylated form to total protein after normalization of the 5 min value of WT neutrophils to an arbitrary value of 1. Data are indicated as means ± SEM of three separate experiments.
Discussion

Previous studies have indicated that DOCK2 is a major Rac GEF acting downstream of GPCRs in neutrophils (14, 15). However, DOCK2 deficiency does not completely abolish chemotactant-induced Rac activation (14), other Rac GEFs are likely to be involved in this process. In this study, we have shown that by deleting both DOCK2 and DOCK5 in mouse BM neutrophils, activation of Rac1 and Rac2 in response to fMLF is markedly reduced. Consistent with this finding, DKO neutrophils exhibited more severe defects in chemotaxis and ROS production than did DOCK2−/− neutrophils. Additionally, we found that fMLF-induced phosphorylations of ERK, Akt, and p38, which are closely associated with Rac activation in neutrophils (3, 6, 7), are severely impaired in DKO neutrophils. The importance of DOCK2 and DOCK5 could be extended to human neutrophils, because fMLF-induced Rac activation, chemotaxis, and ROS production were almost completely lost when human peripheral blood neutrophils were treated with CPYPP (25–27). Our results thus identify DOCK5 as a Rac GEF that acts additively with DOCK2 in the GPCR-mediated signaling pathway in humans and mice.

Several lines of evidence indicate that DH domain–containing GEFs such as P-Rex1 and Vav1 also contribute to GPCR-mediated neutrophil functions (12, 13, 35). Indeed, it was recently reported that fMLF-induced ROS production and migration are reduced to 50% of the WT levels in neutrophils simultaneously lacking both P-Rex1 and Vav1 (36). Because P-Rex1 and Vav1 are normally expressed in DKO neutrophils, it is clear that DOCK2/DOCK5 deficiency does not affect the expression levels of these classical GEFs. The relationship between these DH domain–containing GEFs and DOCK family GEFs is currently unknown. Interestingly, however, a recent study indicated that P-Rex1 acts as a GEF for RhoG in vitro and its deficiency leads to a severe defect in fMLF-induced RhoG activation in neutrophils (37). Activated RhoG binds to ELMO, which then regulates localization and activation of DOCK-A subfamily members by interacting with their N-terminal regions (38–40). Therefore, there may a cross-talk between DH domain–containing GEF-mediated and DOCK family GEF-mediated signaling cascades. In contrast, although P-Rex1 and Vav family proteins do not play major roles in PMA-mediated signal transduction (12, 13, 36), PMA-induced Rac activation and ROS production were severely impaired in DKO neutrophils. Thus, in neutrophils, DOCK2 and DOCK5 are universal Rac GEFs acting in both PI3K-dependent and -independent pathways.

Although NET formation plays a key role in trapping and killing microorganisms, this process also contributes to development of vascular inflammation and autoimmune diseases (30–33). In this study, we have shown that PMA-induced NET formation is almost completely lost for DKO neutrophils. Although the Raf/MEK/ERK pathway has been shown to be important for PMA-induced NET formation (41), phosphorylations of ERK and MEK occurred normally in DKO neutrophils stimulated with PMA. Therefore, it is suggested that DOCK2 and DOCK5 regulate NET formation without affecting the Raf/MEK/ERK pathway, but probably through Rac activation and ROS production.

In conclusion, in this study we have shown that DOCK2 and DOCK5 are the Rac GEFs critical for neutrophil chemotaxis, ROS production, and NET formation in mice and humans. Our results suggest that the Rac GEF activity of DOCK2 and DOCK5 may be a therapeutic target for controlling NET-mediated vascular inflammation and autoimmune diseases.

Acknowledgments

We thank Ayumi Inayoshi, Arisa Aosaka, and Siqinbala (Kyushu University) for technical support and assistance.

Disclosures

The authors have no financial conflicts of interest.

References

REGULATION OF NEUTROPHIL FUNCTIONS BY DOCK2 AND DOCK5


